ライフサイエンスコーパス: IGF

1 IGF-1 (insulin-like growth factor 1) expression was incr

2 IGF-1 (insulin-like growth factor-1) is markedly decreas

3 IGF-1 elevation led to the accumulation of FOXO3A in the

4 IGF-1 receptor (IGF1R) signaling promotes keratinocyte p

5 IGF-I and IGFBP-4 concentrations were markedly altered i

6 Insulin-like growth factor 1 (IGF-1) administration increases fetal cardiomyocyte prol

7 ng in enhanced insulin-like growth factor 1 (IGF-1) expression and activation of proliferative ERK1/2

8 nal actions of insulin-like growth factor 1 (IGF-1) produced by the liver have been well described, b

9 es insulin and insulin-like growth factor 1 (IGF-1) reset circadian clocks in vivo and in vitro by in

10 nduced insulin/insulin-like growth factor 1 (IGF-1) signalling (IIS) via phosphatidyl inositol-3-kina

11 of insulin and insulin-like growth factor 1 (IGF-1).

12 ver function tests, insulin growth factor-1 (IGF-1) and 25-hydroxy vitamin D (25- OH D).

13 (TGFbeta) and insulin-like growth factor-1 (IGF-1) are known to promote fibrosis; however, myofibrob

14 gh circulating insulin-like growth factor-1 (IGF-1) levels increase the risk of prostate cancer.

15 ein (ERG), and insulin-like growth factor-1 (IGF-1) were measured simultaneously with sub-fg/mL LODs

16 stingly, (1-3) insulin-like growth factor-1 (IGF-1), a small peptide under clinical trial testing for

17 rin, and cargo insulin-like growth factor-1 (IGF-1), in thiolated gelatin (gelatin-SH)/ poly(ethylene

18 protein (ERG), insulin-like growth factor-1 (IGF-1), pigment epithelial-derived factor (PEDF), and se

19 Insulin-Like Growth Factor Receptor 1 (IGF-1R) and Epidermal Growth Factor Receptor 3 (ErbB3) h

20 The IGF-1/IGF-2 positions 51/50 and 54/53 did not appear to play c

21 lin and insulin-like growth factors 1 and 2 (IGF-1 and -2) activate insulin receptors (IR-A and -B) a

22 In addition, (1-3) IGF-1 treatment corrected aberrant excitability and netw

23 ckdown of TRalpha1/alpha2 blocked the T(3) + IGF-1 reduction of BrdU uptake and dramatically reduced

24 NH3 blocked the T(3) + IGF-1 reduction of BrdU uptake without altering the phos

25 the NMR structure of the less active Asp-58-IGF-1 variant.

26 in OIR, revealing a new role for p53/let-7b/IGF-1R axis in the retina.

27 nancy-associated plasma protein A (PAPP-A2), IGF-II and IGFBP-5 in 838 children (3-18 years) from the

28 CRC models and the efficacy of MEDI-573, an IGF-1/2-neutralizing antibody.

29 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, func

30 an urgent need for highly specific IGF-1 and IGF-2 antibodies, yet only a short sequence element, i.e

31 he predefined epitopes, namely the IGF-1 and IGF-2 loops.

32 human insulin-like growth factors IGF-1 and IGF-2 makes serological discrimination by immunodiagnost

33 elopment of exceptionally specific IGF-1 and IGF-2 monoclonal antibodies.

34 we investigated the levels of GH, IGF-1 and IGF-binding protein 2 (IGFBP-2) after gastric sleeve sur

35 tions and progressively increasing IL-10 and IGF-1 concentrations.

36 els of hepatocyte growth factor, FGF-13, and IGF-1, but not FGF-2, were significantly higher by up to

37 rats also displayed a decrease in pIRS-2 and IGF-1Rbeta in the NAc (but not VTA), an effect that was

38 ion, including PDGF-A, IGFBP-3, IGFBP-2, and IGF-1.

39 P3 signal (associated with total IGFBP-3 and IGF-II levels) colocalizes with an association with sitt

40 ding, but mutations at IGF-1 position 58 and IGF-2 position 57 affected the binding.

41 cantly improved in dual delivery of ADSC and IGF-1 in Coa encapsulated in gelatin-SH/PEGDA IPN hydrog

42 Pharmacological co-targeting of ASCL1 and IGF-1R results in markedly synergistic effects in ASCL1(

43 association between the FOXO3A/BIM axis and IGF-1R expression in human prostate adenocarcinoma.

44 portant for its binding to IR-A and IR-B and IGF-1R and that A13 is important only for IR-A and IR-B

45 Further, both BDNF and IGF-1 expressions are decreased in MeCP2 T158A mice.

46 RNA level and protein expression of BDNF and IGF-1 in MeCP2 T158A mice.

47 ocyte-derived neurotrophic factors, BDNF and IGF-1, and the glutamate transporter, GLT-1 after ischem

48 ocyte-derived neurotrophic factors, BDNF and IGF-1, as well as the astrocytic glutamate transporter,

49 Here we report that IGF-1 level in blood and IGF-1 signaling demonstrates circadian rhythms.

50 onse to Ti implants, while the Wnt, BMP, and IGF pathways are overexpressed in response to SS implant

51 oxorubicin (DXR) and growth factors (EGF and IGF-1).

52 sults provide a new insight into ERalpha and IGF-1R interference, and open novel perspectives for com

53 in Cu/Zn-SOD, TNF-alpha, TGF-beta1, FASN and IGF-I.

54 with family-interacting protein 3 (FIP3) and IGF-1R, thereby stabilizing FIP3 and enhancing recycling

55 n intake after infancy with later growth and IGF-I are less clear.

56 Y333 in response to stromal signals HGF and IGF-1, respectively, and IGF-1 expression was regulated

57 Insulin and IGF-1 actions in vascular smooth muscle cells (VSMC) are

58 omeostatic functions, we propose insulin and IGF-1 are primary signals of feeding time to cellular cl

59 Insulin and IGF-1 receptor signaling is sufficient to determine esse

60 Previous studies have shown that insulin and IGF-1 signaling in the brain, especially the hypothalamu

61 leting IR decreases responses to insulin and IGF-1.

62 inactivated both insulin receptors (IRs) and IGF-1 receptors (IGF1Rs) in the hippocampus (Hippo-DKO)

63 may contribute to programming lean mass and IGF-I around the time of puberty in boys, but not to adi

64 al inhibition of PRMT1 impaired mERalpha and IGF-1 signaling.

65 glucose, inhibit keratinocyte migration and IGF-1-induced chemotaxis in association with inhibition

66 e expression and downregulation of PPARG and IGF-1, respectively.

67 mal signals HGF and IGF-1, respectively, and IGF-1 expression was regulated by the Sonic Hedgehog (Sh

68 fat mass, DXA lean mass, height z score, and IGF-I concentration.

69 Src and IGF-1R phosphorylated the prometastatic molecule Annexin

70 nsulin-like growth factor (IGF)-1 as well as IGF-binding protein (IGFBP)-3.

71 roles in receptor binding, but mutations at IGF-1 position 58 and IGF-2 position 57 affected the bin

72 ciated activity in response to the autocrine IGF-II stimuli.

73 rescue mechanism controlled by the autocrine IGF-II-insulin receptor-A specific signaling axis.

74 Bioactive IGF was assessed by cell-based IGF receptor activation assay.

75 ) and insulin growth factor-1 receptor beta (IGF-1Rbeta) were assessed in the nucleus accumbens (NAc)

76 ogen signaling, reinforcing the link between IGF-1R and mERalpha.

77 Bioactive IGF was assessed by cell-based IGF receptor activation a

78 prednisolone treatment, total and bioactive IGF-I were increased (p < 0.001 and p < 0.05, respective

79 a exhibited a sustained release of bioactive IGF-1 over 3 weeks.

80 myocyte physiological hypertrophy induced by IGF-1 (insulin-like growth factor 1).

81 to chemotherapy, and that growth induced by IGF-1R and ErbB3 ligands is blocked by the tetravalent b

82 s autocrine-induced EphB4-phosphorylation by IGF-II associates with the increased ubiquitination of E

83 bolism, with their availability regulated by IGF-binding proteins (IGFBPs).

84 for the acute EphB4 PTM-driven regulation by IGF-II.

85 her; 95% CI: -0.07%, 2.78%), and circulating IGF-I (5.67% higher; 95% CI: 0.30%, 11.3%).

86 ed at birth had lower muscle and circulating IGF-I, decreased muscle and body mass, and impaired musc

87 igate the impact of the elevated circulating IGF-1 on prostate cancer development in vivo.

88 eliorates symptoms and increases circulating IGF-I, but prednisolone induces catabolism, whereas infl

89 se model (HIT) to increase their circulating IGF-1 levels to investigate the impact of the elevated c

90 th correlated with birth weight, circulating IGF-I, and total and abdominal fat at age 2 weeks.

91 However, whether circulating IGF-1 levels directly aggravate prostate cancer remains

92 PAPP-A can cleave IGF binding protein-4 (IGFBP-4), upon which IGF-I is lib

93 pression in myofibroblasts; (4) demonstrates IGF-1R activation is essential to support TGFbeta-driven

94 r data support a role for macrophage-derived IGF-1 as a key neurotrophic and sensitizing factor in en

95 ally, we demonstrate that macrophage-derived IGF-1 promotes sprouting neurogenesis and nerve sensitiz

96 e data identify that dopamine neuron-derived IGF-1 acts as a regulator of dopamine neurons and regula

97 ditional deletion of dopamine neuron-derived IGF-1 in adult mice leads to decrease of dopamine conten

98 escribed, but the role of neuronally derived IGF-1 remains largely unexplored.

99 ies bound with high affinity to the distinct IGF epitopes displayed on the protein scaffolds, as well

100 his work is to determine the effects of dual IGF-1R/ErbB3 inhibition on ovarian cancer cell signaling

101 Suppression of rRNA synthesis during IGF-1 treatment did not prevent early increases in AKT (

102 mation, adipokines, endothelial dysfunction, IGF axis, and iron store plus age and BMI at blood colle

103 d gestation (term = 147 d), receiving either IGF-1 LR3 or vehicle.

104 cell activity and is modulated by endogenous IGF-1/VEGF-A signaling.

105 We show that Rab7a siRNA inhibition enhances IGF-1 and HGF signalling in beta cells and increases exp

106 Coa-mediated delivery of chondrogenic factor IGF-1 with the aid of adipose-derived stem cells (ADSCs)

107 etion by insulin/insulin-like growth factor (IGF) 2-AKT signaling.

108 Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and ident

109 role of TEC-expressed insulin growth factor (IGF) binding protein-7 (IGFBP7/angiomodulin).

110 long-lived daf-2/insulin like growth factor (IGF) receptor and short lived daf-16/FOXO transcription

111 onserved insulin/insulin-like growth factor (IGF) signaling (IIS) has been identified as a major phys

112 maternal insulin/insulin-like growth factor (IGF) signaling (IIS) increase oocyte provisioning of vit

113 owth hormone and insulin-like growth factor (IGF) system is integral to human growth.

114 egulation of the insulin-like growth factor (IGF) system.

115 e "Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor

116 h T(3) (1.5 nm), insulin-like growth factor (IGF)-1 (1 mug mL(-1) ) or a combination in the presence

117 serum levels of insulin-like growth factor (IGF)-1 as well as IGF-binding protein (IGFBP)-3.

118 e by suppressing insulin-like growth factor (IGF)-mediated Akt-Tor and Erk signaling.

119 -13, and type 1 insulin-like growth factor (IGF-1), which enhance neuronal survival and functions, w

120 een mature human insulin-like growth factors IGF-1 and IGF-2 makes serological discrimination by immu

121 Insulin-like growth factors (IGFs) are essential for local skeletal muscle growth and

122 Insulin-like growth factors (IGFs), specifically IGF1 and IGF2, promote glucose metab

123 proliferation and heart mass, but how fetal IGF-1 treatment affects coronary growth and function is

124 cling compartment members (Rab11a and FIP3), IGF-1R, and Akt phosphorylation.

125 was preserved on a per-gram basis following IGF-1 treatment, adenosine and nitric oxide contributed

126 d domains being proposed to be essential for IGF-1 mediated hypertrophy.

127 Our results suggest a role for IGF-1R and ErbB3 in driving chemotherapy resistance of o

128 ng recipients with immediate graft function (IGF), but only with harms among recipients with DGF.

129 GH, IGF-1 and IGFBP-2 levels were evaluated by ELISA at base

130 GH, IGF-1, and IGFBP-2 were not correlated with insulin or l

131 his study, we investigated the levels of GH, IGF-1 and IGF-binding protein 2 (IGFBP-2) after gastric

132 males potentially by interacting with the GH/IGF-1 axis.

133 abolism (FASN and CYP7A1), and organ growth (IGF-I) related genes were affected by the dietary treatm

134 early childhood (median 3.2 y) with height, IGF-I, and measures of adiposity and lean mass in mid-ch

135 Higher IGF-I concentration was associated with increased risks

136 s the AP2A1/2 pathway predominates at higher IGF-1 concentrations.

137 ntake is consistently associated with higher IGF-I concentrations and more rapid growth, but associat

138 in scaffolds, as well as on the mature human IGF isoforms.

139 al treatment with rhIGF-1 (recombinant human IGF-1)/BP3 (binding peptide 3) improves lung growth and

140 Circulating insulin-like growth factor I (IGF-I) is positively associated with the risks of colore

141 reduced serum insulin-like growth factor I (IGF-I).

142 ps mediated by insulin-like growth factor I (IGF-I).

143 S of measured serum protein levels of IGF-I, IGF binding protein-3 (IGFBP-3), pregnancy-associated pl

144 Circulating levels of IGF-I, IGF-II, IGFBP-3, PAPP-A, and STC2 were measured by immun

145 ary function in advanced IPF; (2) identifies IGF-1's C1 promoter as mediating the increase in IGF-1 t

146 nistration of insulin-like growth factor II (IGF-II), a polypeptide that crosses the blood-brain barr

147 rological discrimination by immunodiagnostic IGF tests a challenging task.

148 Importantly, IGF-1 supplementation or anti-IL-6 treatment rescued the

149 in proliferation and differentiation, and in IGF and TGFbeta signalling pathways.

150 that mutagenesis and skin carcinogenesis in IGF-1-deficient geriatric skin may be caused by defects

151 There was no change in IGF-1 level from before to after surgery.

152 1's C1 promoter as mediating the increase in IGF-1 transcription by TGFbeta in pulmonary fibroblasts;

153 vides the mechanism for circadian rhythms in IGF signaling in vivo.

154 -mediated coronary vasodilation similarly in IGF-1-treated and Control fetuses, and the relationships

155 ulin residues and the equivalent residues in IGFs.

156 ting FFAs and adipokines/cytokines including IGF-1, VEGF, and MCP-1, along with decreased AR, Ki67, a

157 an cancer cell lines revealed that increased IGF-1R cell surface expression correlates with decreased

158 s known that growth factors such as insulin, IGF-1 and HGF support beta cell growth and survival, but

159 Tyramine stimulates the insulin-IGF-1 signalling (IIS) pathway and precludes the inducti

160 founds effects on lifespan of daf-2 (insulin/IGF-1 signalling), daf-12 (steroid hormone signalling),

161 l cells-by promoting food intake and insulin/IGF signalling.

162 d insulin resistance (i.e. decreased insulin/IGF-1) have been reported in other neurodegenerative dis

163 In addition, in the hippocampus, insulin/IGF-1 signaling is important for spatial learning and me

164 ellogenin-mediated intergenerational insulin/IGF-to-insulin/IGF signaling mediates adaptation to nutr

165 In well-fed males, insulin-like (insulin/IGF-1 signaling [IIS]) and transforming growth factor be

166 te longevity under conditions of low insulin/IGF signalling and stress.

167 ne (JH) and the two nutrient sensors insulin/IGF signaling (IIS) and target of rapamycin complex1 (TO

168 The insulin/IGF signalling pathway impacts lifespan across distant t

169 The Insulin/IGF-1 signalling (IIS) pathway plays an essential role i

170 The insulin/IGF-1 signalling pathway is a key regulator of metabolis

171 lifespan through the function of the insulin/IGF-like signaling and its effector DAF-16/FOXO transcri

172 Thus, insulin/IGF-1 signaling has common roles in the hippocampus and

173 ody organs that sense and respond to insulin/IGF-1, the adipose tissue has a central role in both the

174 ted intergenerational insulin/IGF-to-insulin/IGF signaling mediates adaptation to nutrient availabili

175 ogenes involved in PDGF, EGFR, VEGF, insulin/IGF/MAPKK, FGF, Hedgehog, TGFbeta, and PI3K signaling pa

176 spatial learning and memory whereas insulin/IGF-1 signaling in the central amygdala controls thermog

177 at day 14, suggesting the GH effect on liver IGF-I production was unaffected by skeletal UL.

178 The Flot-1 pathway is more responsive to low IGF-1 concentrations, whereas the AP2A1/2 pathway predom

179 between anthropometric z-scores and the mean IGF-1 and (25- OH D) values (p > 0.05).

180 The mean IGF-1 and (25- OH D) values were significantly correlate

181 (lymphocyte, alpha-linoleic acid metabolism, IGF regulation) including eleven genes as optimal marker

182 therapy inhibiting (anti-IL-6) or mimicking (IGF-1) the cardiac hMSC secretome can rescue arrhythmia

183 Thus, IGFBP-4 may modulate IGF bioavailability in IBD.

184 d plasma protein-A (PAPP-A), which modulates IGF-I activity.

185 Deletion of muscle IGF-I transiently impairs growth and progressively disru

186 ge-dependent manner, thus positioning muscle IGF-I maintenance to be critical for both muscle growth

187 We assert that muscle IGF-I independently modulates anabolism and metabolism i

188 rther studies have demonstrated that nuclear IGF-1R (nIGF-1R) physically and functionally interacts w

189 Absence of IGF-1R or mutation of Tyr-60, Tyr-133, or Tyr-250 in PCN

190 re consistent with a positive association of IGF-I with cancers at several sites.

191 Concentrations of IGF-1 were elevated in peritoneal fluid from women with

192 dosome-mediated recycling and degradation of IGF-1R during physiologic hypertrophy has not been inves

193 work was to determine whether the effects of IGF-I on growth and metabolism could be separated.

194 macrophages exhibit increased expression of IGF-1 in an in vitro model of endometriosis-associated m

195 The differential expressions of IGF-1R, FOXO3A, and BIM in the benign versus malignant p

196 which, in turn, leads to hyperactivation of IGF-1R signaling.

197 These findings expand our knowledge of IGF-1's role as a novel fibrotic-switch, bringing us one

198 observational evidence that higher levels of IGF-1 appeared to confer some protection against hearing

199 Immunoreactivity and mRNA levels of IGF-1, TGF-beta1, and beta3-adrenoceptor were increased

200 ncreased total and plasma membrane levels of IGF-1R and increased phosphorylation of Akt.

201 med GWAS of measured serum protein levels of IGF-I, IGF binding protein-3 (IGFBP-3), pregnancy-associ

202 Circulating levels of IGF-I, IGF-II, IGFBP-3, PAPP-A, and STC2 were measured b

203 ze the genetic regulation of serum levels of IGF-related proteins in childhood.

204 , we investigated the oncogenic potential of IGF-2 in IGF2-overexpressing CRC models and the efficacy

205 through FIP3-mediated endosomal recycling of IGF-1R.

206 stabilizing FIP3 and enhancing recycling of IGF-1R.

207 ing the FIP3-mediated endosomal recycling of IGF-1R.

208 ot appear to extend beyond the regulation of IGF and IGFBP-4, as neither PAPP-A nor STC2 were discern

209 sting findings included a protective role of IGF-1 (insulin-like growth factor 1) in systolic blood p

210 eded to further assess how broad the role of IGF-I is in cancer development.

211 ing hMSCs exhibited >25x higher secretion of IGF (insulin-like growth factor)-1 compared with failing

212 enotype, thereby increasing the secretion of IGF-1 and CCL20, which promoted tumor progression and st

213 ple types of muscle atrophy via targeting of IGF-1 and PI3K(p85alpha), and that suppression of miR-29

214 ever, myofibroblast specific upregulation of IGF-1 in the initiation and progression of TGFbeta-induc

215 rent study (1) documents the upregulation of IGF-1 via TGFbeta in myofibroblasts and fibrotic lung ti

216 the distribution, function, and activity of IGFs in the pericellular space.

217 g via signaling that is often independent of IGFs.

218 oles, we delete insulin receptor (SMIRKO) or IGF-1 receptor (SMIGF1RKO) in VSMC and in mice.

219 on in malignant mesothelioma cells and other IGF-II-secreting cancers (IGF2omas).

220 phospho-IGF-1R levels were significantly higher in females compa

221 (GLUT-3) and increased (P = 0.037) placental IGF-2 mRNA expression.

222 Additionally, plasma IGF levels were assessed in an AAb(+) cohort monthly for

223 human insulin-like growth factor 1 receptor (IGF-1R) in skeletal muscle, and (2) Obesity-dependent db

224 eptors (IR-A and -B) and the IGF-1 receptor (IGF-1R) is crucial for understanding the difference in t

225 the IGF-1 and its receptor, IGF-1 receptor (IGF-1R), and subsequent activation of the protein kinase

226 ating insulin-like growth factor-1 receptor (IGF-1R)-mediated ERK1/2 signaling.

227 insulin-like growth factor type 1 receptor (IGF-1R).

228 d the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease.

229 f the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the u

230 been ascribed to the IGF-1 and its receptor, IGF-1 receptor (IGF-1R), and subsequent activation of th

231 es expression of the growth factor receptors IGF-1R and c-Met.

232 T(3) reduced IGF-1 stimulated proliferation by ~50% in 100 dGA and by

233 els and activated PP2A, which down-regulated IGF signaling and promoted the quiescent state.

234 nt results showed that SCI bladders released IGF-1 and TGF-beta1 to stimulate elastin and collagen fo

235 Subsequently, released IGF-1 from Coa could effectively induce chondrogenic dif

236 rations and cancer incidence, using repeated IGF-I measurements from up to 14,149 participants to cor

237 They also show that calorie restriction, IGF-1R signaling, and body temperature, three of the mai

238 We discovered that dopamine neurons secrete IGF-1 from the cell bodies following depolarization, and

239 eased upon neutralization of cancer-secreted IGF-II.

240 etermine associations between baseline serum IGF-I concentrations and cancer incidence, using repeate

241 , we investigated associations between serum IGF-I concentrations and incidence of less common cancer

242 GH treatment increased serum IGF-I levels similarly in TBI, UL and TBI-UL groups at d

243 We also measured serum IGFs from a cohort of fasted subjects with type 1 diabet

244 lin/insulin-like growth factor-1 signalling (IGF-1) and insulin resistance (i.e. decreased insulin/IG

245 otein-3 (IGFBP-3) belongs to a family of six IGF binding proteins.

246 the fossil record, the O. bambolii skeleton IGF 11778 has been, for decades, at the center of intens

247 Chimeric SlyD-IGF proteins allowed for the development of exceptionall

248 or the development of exceptionally specific IGF-1 and IGF-2 monoclonal antibodies.

249 There is an urgent need for highly specific IGF-1 and IGF-2 antibodies, yet only a short sequence el

250 se model, Hi-Myc mice, with a liver-specific IGF-1 transgenic mouse model (HIT) to increase their cir

251 We generated muscle-specific IGF-I-deficient (MID) mice that afford inducible deletio

252 In sum, IGFs are dysregulated both before and after the clinical

253 These findings support IGF-1 as a potential strategy to increase cardiac myocyt

254 he tetravalent bispecific antibody targeting IGF-1R and ErbB3, istiratumab.

255 eurons electroporated with a shRNA targeting IGF-1 receptor failed to migrate to the upper cortical l

256 ells electroporated with the shRNA targeting IGF-1 receptor were unable to form an axon and, therefor

257 r ER and let-7 in lung fibrosis, and 2) that IGF may stimulate ER in an E(2)-independent manner.

258 ll bodies following depolarization, and that IGF-1 controls release of dopamine in the ventral midbra

259 We conclude that IGF-1-stimulated fetal myocardial growth is accompanied

260 Here, we found that IGF-1 treatment of MCF-7 cells induced rapid ERalpha met

261 We propose that IGF-1 Glu-58 interacts with IGF-1R Arg-704 and belongs t

262 Here we report that IGF-1 level in blood and IGF-1 signaling demonstrates ci

263 In neurons in culture we showed that IGF-1 receptor activation is important for growth cone a

264 The IGF-1/IGF-2 positions 51/50 and 54/53 did not appear to

265 vate insulin receptors (IR-A and -B) and the IGF-1 receptor (IGF-1R) is crucial for understanding the

266 Under these conditions, the IGF-I receptor signals through an alternate scaffold pro

267 yet only a short sequence element, i.e. the IGF loop, provides enough difference in sequence to disc

268 to be a limiting step in muscle growth, the IGF-1 growth pathway remained functional despite the del

269 Cells lacking the IGF-1 receptor remain arrested as multipolar forming a h

270 ation of the predefined epitopes, namely the IGF-1 and IGF-2 loops.

271 Here we investigate features of the IGF 11778 pelvis and lumbar region based on torso prepar

272 ctively expressed multiple components of the IGF system.

273 1 in alveolar fibroblasts or deletion of the IGF-1 receptor from ILC precursors interrupted ILC3 biog

274 atio to receive intravenous infusions of the IGF-IR inhibitor teprotumumab (10 mg per kilogram of bod

275 These data suggest that citrate acts on the IGF-1R-AKT-PTEN-eIF2a pathway.

276 Our findings suggest that targeting the IGF-1/FOXO3A/BIM signaling axis could be an attractive s

277 Thus, the IGF system represents a previously unappreciated pathway

278 eral crucial interpretations relating to the IGF 11778 anterior inferior iliac spine and lumbar verte

279 pertrophy has primarily been ascribed to the IGF-1 and its receptor, IGF-1 receptor (IGF-1R), and sub

280 to contribute to muscle hypertrophy via the IGF-1 growth pathway.

281 progression of murine lung fibrosis with the IGF-1R inhibitor OSI-906.

282 In agreement with this, IGF-1 robustly induced BNIP3 accumulation in mitochondri

283 growth-regulating mechanisms acting through IGF-related genes in ways that are not reflected in meas

284 Signaling through IGF receptor (IGF1R) activated the protein kinase B-mamm

285 interacts with IGF-1R Arg-704 and belongs to IGF-1 site 1, a finding supported by the NMR structure o

286 we showed that PRMT1 bound constitutively to IGF-1R and that PRMT1 became activated upon IGF-1 stimul

287 MT1 and triggered the binding of mERalpha to IGF-1R.

288 ILC1s or ILC2s, were similarly responsive to IGF signaling.

289 h pre-type 1 diabetes, suggesting that total IGF levels may reflect bioactivity.

290 Upon infliximab treatment, total IGF-I levels were augmented (p < 0.05), yet IGF bioactiv

291 by promoting degradation of an unstimulated IGF-1R, but protecting the receptor against agonist-indu

292 IGF-1R and that PRMT1 became activated upon IGF-1 stimulation.

293 eased in normal preterm infants, but whether IGF-1 treatment can prevent BPD or PH is unknown.Objecti

294 This prompted us to investigate whether IGF signaling is essential for mitochondrial maintenance

295 tiated in a cohort of breast tumors in which IGF-1R expression was positively correlated with ERalpha

296 IGF binding protein-4 (IGFBP-4), upon which IGF-I is liberated.

297 We propose that IGF-1 Glu-58 interacts with IGF-1R Arg-704 and belongs to IGF-1 site 1, a finding su

298 s was increased after both AE and NMES, with IGF-1 being a signaling molecule that correlated with MC

299 (aHR=(0.86)0.89(0.93)) among recipients with IGF.

300 IGF-I levels were augmented (p < 0.05), yet IGF bioactivity remained unaltered.